Re: Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)
It's true...what they say....
You can't gallop any faster than the horse you are riding. But the startup of this trial begs the question, "Why now?"
The NCCN has had a Category 2a listing for cabozantinib for some ~3 years in RET-driven NSCLC. The topic of this NSCLC trial structure and biometrics has been discussed ad nauseum by members of this board dating back at least 3 years, and EXEL management has been chastised at length for omitting the development of Cabo in the lung space. What gives?
What has changed? Why did this take so long?